Investor Presentation | October 2013 The future of drug discovery has arrived Reducing development time, cost & risk

2 TSXV: COT When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward- looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. Disclaimer

3 TSXV: COT Who we are… An innovative, drug discovery, preclinical development and intellectual property company 3 TSXV: COT Critical Outcome Technologies Inc. 3

4 TSXV: COT Investment highlights Proprietary platform technology reduces time, cost & risk of bringing new drugs to market Two-pronged commercial validation and revenue strategy Actively pursuing licensing of lead cancer drug candidate (COTI-2) with Pharma – leading to profitability

5 TSXV: COT Conventional drug development is a long & expensive process characterized by a high risk of failure 11 – 15 years $1 billion or more 1 FDA approval 5

6 TSXV: COT Years Preclinical Development Steps Reduce drug discovery timeline by years Save significant $$$ Increase revenue period under patent protection We rapidly accelerate drug discovery

7 TSXV: COT Proprietary scalable AI platform Computational simulation of traditional ‘wet lab’ drug discovery process (FDA,HC) Failed attempts occur in computer simulations, not the ‘research bench’ Improving the probability of clinical & commercial success 7 TSXV: COT CHEMSAS® - Our competitive advantage

8 TSXV: COT Two-pronged commercialization strategy R&D collaborations for revenue & 3 rd party validation of the CHEMSAS® platform Licensing our own drug compounds

9 TSXV: COT The opportunity Major Pharma reducing internal R&D o Low R&D productivity o Focusing on marketing & distribution – control the end customer Significant opportunities for R&D collaborations o Leverage complementary expertise / capabilities

10 TSXV: COT Typical CHEMSAS® R&D collaboration Partner has specific novel drug target Receive an upfront development fee from Partner and build a compound library Library testing and evaluation at Partner’s expense We retain IP ownership of compounds and all data Partner proceeds with development under a license with upfront, milestone, and royalty payments

11 TSXV: COT A collaboration can bring in multiple milestone payments providing significant ongoing revenues Scalability of CHEMSAS® enables multiple concurrent collaboration revenue opportunities Three active collaborations proceeding well o Western University o Delmar Chemicals o Major Pharma Company Seeking more CHEMSAS® collaborations CHEMSAS® R&D collaborations

12 TSXV: COT Licensing our own compounds Actively pursuing licensing of lead cancer drug candidate, COTI-2, with a Pharma Company in a transaction making us immediately profitable Other internal drug development projects in queue (i.e. AML)

13 TSXV: COT Effective against cancers with mutations of the p53 gene > 50% of all human cancers have a p53 mutation About COTI-2 p53 dependent mechanism of action confirmed by Dr. Gordon Mills at the University of Texas, MD Anderson Cancer Center In final two-species toxicity studies prior to FDA filing in early 2014 enabling human trials

14 TSXV: COT 4 U.S. patents granted – strengthening COTI-2’s value proposition Composition of matter granted out to 2030 Patents pending in USA, Europe, Canada and Japan Patent strategy preserves downstream patent filing opportunities for potential extension of market exclusivity We own all intellectual property with no license obligations COTI-2: Intellectual property overview

15 TSXV: COT Why license COTI-2? Drug development is a long and expensive process Our core competence is accelerating drug discovery, not drug development Recent preclinical oncology licensing deals included: o Upfront payments of approx. $5-$15 million o Milestone payments between $120-$288 million o Royalties on net sales

16 TSXV: COT Investor relations Engaged Heisler Communications to implement comprehensive Canadian IR strategy o Strengthen relationships with current shareholders plus outreach to new investor audiences Engaged Consulting For Strategic Growth 1/LaunchPad to implement comprehensive US IR strategy o Stanley Wunderlich, o Bob Giordano,  A very experienced team in the Life Sciences sector

17 TSXV: COT Summary Proprietary technology reduces time, cost & risk of bringing new drugs to market Two-pronged commercial validation and revenue strategy Actively pursuing licensing of lead cancer drug candidate (COTI-2) with pharma – leading to profitability

The future of drug discovery has arrived Reducing development time, cost & risk

19 TSXV: COT Trading Stock ExchangeTSX Venture SymbolCOT 52 Week Rolling low/high (1) $0.10 – 0.38 Capital Cash (2) $ 1.3M Basic Shares Outstanding92,682,499 Options Outstanding5,273,569 Warrants Outstanding44,869,466 Fully Diluted Shares Outstanding142,825,534 Contingent Rights Outstanding (3) 715,720 Board & management control (4) 22.4% Contact Info AddressSuite 213, 700 Collip Circle London, Ontario N6G 4X8 Phone Fax Websitewww.criticaloutcome.com ChairmanMr. John Drake President, CEO & CSO Dr. Wayne Danter Chief Financial Officer Gene Kelly (1)As at Sept 30/13 (2)Cash = cash and cash equivalents at Aug 31/13 (3)Contingent rights not included in fully diluted under IFRS (4)On a fully diluted basis Key company facts

20 TSXV: COT CHEMSAS Validation - R&D Pipeline